JP2019512005A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512005A5
JP2019512005A5 JP2018540838A JP2018540838A JP2019512005A5 JP 2019512005 A5 JP2019512005 A5 JP 2019512005A5 JP 2018540838 A JP2018540838 A JP 2018540838A JP 2018540838 A JP2018540838 A JP 2018540838A JP 2019512005 A5 JP2019512005 A5 JP 2019512005A5
Authority
JP
Japan
Prior art keywords
raav
hidua
pharmaceutical composition
patient
suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018540838A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512005A (ja
JP7360241B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/016133 external-priority patent/WO2017136500A1/en
Publication of JP2019512005A publication Critical patent/JP2019512005A/ja
Publication of JP2019512005A5 publication Critical patent/JP2019512005A5/ja
Priority to JP2023023041A priority Critical patent/JP2023062088A/ja
Application granted granted Critical
Publication of JP7360241B2 publication Critical patent/JP7360241B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018540838A 2016-02-03 2017-02-02 ムコ多糖症i型を治療するための遺伝子治療 Active JP7360241B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023023041A JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201662290547P 2016-02-03 2016-02-03
US62/290,547 2016-02-03
US201662323271P 2016-04-15 2016-04-15
US62/323,271 2016-04-15
US201662337178P 2016-05-16 2016-05-16
US62/337,178 2016-05-16
US201662367798P 2016-07-28 2016-07-28
US62/367,798 2016-07-28
US201762452560P 2017-01-31 2017-01-31
US62/452,560 2017-01-31
PCT/US2017/016133 WO2017136500A1 (en) 2016-02-03 2017-02-02 Gene therapy for treating mucopolysaccharidosis type i

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023023041A Division JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2019512005A JP2019512005A (ja) 2019-05-09
JP2019512005A5 true JP2019512005A5 (https=) 2020-03-12
JP7360241B2 JP7360241B2 (ja) 2023-10-12

Family

ID=58108727

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018540838A Active JP7360241B2 (ja) 2016-02-03 2017-02-02 ムコ多糖症i型を治療するための遺伝子治療
JP2023023041A Pending JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023023041A Pending JP2023062088A (ja) 2016-02-03 2023-02-17 ムコ多糖症i型を治療するための遺伝子治療

Country Status (11)

Country Link
US (3) US10973929B2 (https=)
EP (1) EP3411488A1 (https=)
JP (2) JP7360241B2 (https=)
KR (2) KR20250171426A (https=)
AU (3) AU2017215211C1 (https=)
BR (1) BR112018015751A2 (https=)
CA (1) CA3012195A1 (https=)
IL (1) IL260959B2 (https=)
MA (1) MA43968A (https=)
SG (2) SG10201912758TA (https=)
WO (1) WO2017136500A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2984166T1 (sl) * 2013-03-15 2020-09-30 The Trustees Of The University Of Pennsylvania Sestavki za zdravljenje MPSI
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
EP3411488A1 (en) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
JP7455579B2 (ja) 2017-02-28 2024-03-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 新規アデノ随伴ウイルス(aav)クレードfベクター及びその用途
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
KR102719222B1 (ko) 2017-05-11 2024-10-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 신경 세로이드 지질갈색소증에 대한 유전자 요법
MA50016A (fr) 2017-07-06 2020-07-08 Univ Pennsylvania Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i
TWI835747B (zh) 2017-09-22 2024-03-21 賓州大學委員會 用於治療黏多醣病 ii 型之基因治療
CN107699590A (zh) * 2017-10-13 2018-02-16 成都中医药大学 一种制备重组人α‑L‑艾杜糖醛酸酶的方法
KR102823833B1 (ko) 2017-11-30 2025-06-23 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 뮤코다당류증 iiia형에 대한 유전자 요법
KR20200104864A (ko) 2017-11-30 2020-09-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 뮤코다당류증 iiib형에 대한 유전자 요법
IL280198B2 (en) * 2018-07-18 2026-01-01 Regenxbio Inc Treatment of mucopolysaccharidosis I with fully glycosylated human iduronidase-alpha-L (idus)
CN113438954A (zh) 2018-10-01 2021-09-24 宾夕法尼亚州大学信托人 可用于治疗gm1神经节苷脂病的组合物
US11345929B2 (en) 2018-10-25 2022-05-31 Regeneron Pharmaceuticals, Inc. Methods for analysis of viral capsid protein composition
EP3894864A2 (en) * 2018-12-10 2021-10-20 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
WO2020132455A1 (en) * 2018-12-21 2020-06-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
EP3826664A4 (en) * 2019-02-06 2022-10-26 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type i
BR112021015817A2 (pt) 2019-02-22 2021-10-13 The Trustees Of The University Of Pennsylvania Vírus adeno-associado recombinante para tratamento de neurodegeneração com início na idade adulta associado a grn
WO2021081217A1 (en) * 2019-10-23 2021-04-29 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2021150570A1 (en) * 2020-01-22 2021-07-29 Regenxbio Inc. Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua)
MX2022009462A (es) * 2020-02-02 2022-11-10 Univ Pennsylvania Composiciones útiles para tratar la gangliosidosis gm1.
US20230304034A1 (en) 2020-05-12 2023-09-28 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
EP4204014A1 (en) * 2020-08-26 2023-07-05 The Trustees of The University of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
AU2021356684A1 (en) 2020-10-09 2023-05-11 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
EP4236968A4 (en) * 2020-10-30 2024-03-27 Immusoft Corporation Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
WO2023049846A1 (en) * 2021-09-24 2023-03-30 The Trustees Of The University Of Pennsylvania Compositions useful for treatment of charcot-marie-tooth disease
CA3236188A1 (en) * 2021-10-27 2023-05-04 The University Of North Carolina At Chapel Hill Aav-idua vector for treatment of mps i
WO2023087019A2 (en) 2021-11-15 2023-05-19 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2023102517A1 (en) 2021-12-02 2023-06-08 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of fabry disease
WO2023172975A1 (en) * 2022-03-08 2023-09-14 University Of Massachusetts Methods of raav packaging
US20250250326A1 (en) 2022-04-06 2025-08-07 The Trustees Of The University Of Pennsylvania Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors
JP2025512969A (ja) 2022-04-06 2025-04-22 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Her2陽性転移性乳がん及び他のがんを治療するための組成物及び方法
CN115838709A (zh) * 2022-11-29 2023-03-24 武汉禾元生物科技股份有限公司 以基因工程水稻表达和制备重组人艾杜糖苷酸酶的方法
EP4724085A1 (en) 2023-06-12 2026-04-15 The Trustees of The University of Pennsylvania Aav gene therapy for mucopolysaccharidosis iiib
AR133098A1 (es) 2023-06-29 2025-08-27 Univ Pennsylvania Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen
IL326390A (en) 2023-08-10 2026-04-01 Univ Pennsylvania Compositions and methods for treating spinal muscular atrophy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
CA2328518A1 (en) 1998-05-13 1999-11-18 Harbor-Ucla Recombinant (alpha)-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
US6426208B1 (en) 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
RU2196988C2 (ru) 2000-04-19 2003-01-20 Государственный новосибирский областной клинический диагностический центр Способ диагностики мукополисахаридозов
NZ532635A (en) 2001-11-13 2007-05-31 Univ Pennsylvania A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003302724A1 (en) 2002-08-13 2004-07-09 Mcivor, Scott, R. Methods of using vectors to treat metabolic disorders
US7155804B2 (en) 2003-09-17 2007-01-02 Moog Inc. Method of forming an electric motor
CN1856576B (zh) 2003-09-30 2011-05-04 宾夕法尼亚州立大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
WO2006110689A2 (en) 2005-04-07 2006-10-19 The Trustees Of The University Of Pennsylvania Method of increasing the function of an aav vector
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
US20090062144A1 (en) 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US9415121B2 (en) 2008-12-19 2016-08-16 Nationwide Children's Hospital Delivery of MECP2 polynucleotide using recombinant AAV9
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2826860B1 (en) 2010-04-23 2018-08-22 University of Massachusetts CNS targeting AAV vectors and methods of use thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
DK2675902T3 (da) 2011-02-17 2019-06-03 Univ Pennsylvania Sammensætninger og fremgangsmåder til at ændre vævsspecificitet og forbedre aav9-medieret genoverførsel
HRP20171334T1 (hr) 2011-04-22 2017-11-17 The Regents Of The University Of California Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe
DK3444342T3 (da) 2012-07-11 2020-08-24 Sangamo Therapeutics Inc Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
WO2014125647A1 (ja) 2013-02-18 2014-08-21 富士通オプティカルコンポーネンツ株式会社 光受信装置
SI2984166T1 (sl) 2013-03-15 2020-09-30 The Trustees Of The University Of Pennsylvania Sestavki za zdravljenje MPSI
CN105377039A (zh) 2013-05-15 2016-03-02 明尼苏达大学董事会 腺相关病毒介导的基因向中枢神经系统转移
US9585971B2 (en) 2013-09-13 2017-03-07 California Institute Of Technology Recombinant AAV capsid protein
BR112017005892A2 (pt) 2014-09-24 2017-12-12 Hope City variantes de vetor de vírus adeno-associado para edição de genoma de alta eficácia e métodos da mesma
CN107002096A (zh) 2014-10-06 2017-08-01 阿罗根有限公司 基于aav的基因疗法
HK1256341A1 (zh) 2015-05-15 2019-09-20 明尼苏达大学董事会 用於治疗性递送到中枢神经系统的腺相关物
US10604747B2 (en) 2015-08-06 2020-03-31 Academia Sinica Engineered enzyme for enzyme replacement therapy
US20180236105A1 (en) 2015-10-23 2018-08-23 University Of Iowa Research Foundation Methods for treating neurodegenerative diseases using gene therapy to delay disease onset and progression while providing cognitive protection
WO2017100676A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
EP3387138B1 (en) 2015-12-11 2022-01-26 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
US11028372B2 (en) 2015-12-11 2021-06-08 The Trustees Of The University Of Pennsylvania Scalable purification method for AAVRH10
US11015173B2 (en) 2015-12-11 2021-05-25 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV1
CA3010738A1 (en) 2016-01-15 2017-07-20 Sangamo Therapeutics, Inc. Methods and compositions for the treatment of neurologic disease
EP3411488A1 (en) 2016-02-03 2018-12-12 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type i
MA50016A (fr) 2017-07-06 2020-07-08 Univ Pennsylvania Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i

Similar Documents

Publication Publication Date Title
JP2019512005A5 (https=)
JP2019518002A5 (https=)
Pipe et al. Clinical considerations for capsid choice in the development of liver-targeted AAV-based gene transfer
US12370268B2 (en) Fabry disease gene therapy
JP6767483B2 (ja) 遺伝子療法のための、改変されたフリードライヒ運動失調症遺伝子およびベクター
Choudhury et al. In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy
JP7532360B2 (ja) ウィルソン病を処置するための組成物および方法
JP2023036618A (ja) コロイデレミアの遺伝子治療に使用するためのaavベクター
JP2023106497A (ja) 減少した免疫反応性を有するaavビリオン、およびその使用
JP2023538129A (ja) 好ましい発現レベルを有するアデノ随伴ウイルス組成物
JP7082050B2 (ja) 脊髄性筋萎縮症の処置において有用なアデノ-関連ウイルスベクター
JP6978407B2 (ja) Glp−1及び代謝性疾患を治療するための組成物におけるその使用
JP7061067B2 (ja) クリグラー・ナジャー症候群の処置のための組成物
JP2022116045A (ja) アルデヒドデヒドロゲナーゼ欠損症の治療のための遺伝子治療
JP2020503265A (ja) メチル−cpg結合タンパク質2をコードする組換えアデノ随伴ウイルスの髄腔内送達
JP2023526498A (ja) グルコース-6-ホスファターゼ(G6Pase-a)をコードする遺伝子治療用ベクター
US20250161493A1 (en) Compositions and methods for in vivo nuclease-mediated treatment of ornithine transcarbamylase (otc) deficiency
WO2024060463A1 (zh) 改进的人凝血因子viii基因表达盒及其应用
US20230340526A1 (en) Novel aav3b variants that target hepatocytes and evade the humoral immune response
JP2023545384A (ja) 中枢神経系または筋肉送達のための組換えアデノ随伴ウイルス
WO2025039622A1 (zh) 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途
EP4413019A2 (en) Recombinant adeno-associated viruses for cns tropic delivery
CN121175424A (zh) 一种携带smn基因表达框的病毒载体及其用途
BR112017027956B1 (pt) Vetores de vírus adenoassociado recombinante, uso e método de produção dos mesmos, e composição farmacêutica